These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9625857)

  • 21. Radiotherapy as a cisplatin-sensitizer in a resistant ovarian carcinoma cell line.
    Siler DF; Wheeless CR; Dubin NH
    Cancer; 1996 May; 77(9):1850-3. PubMed ID: 8646684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of human tumour cell responses to cisplatin and ZD0473 with and without irradiation.
    Raaphorst GP; Yang DP; Li LF; Malone S
    Anticancer Res; 2004; 24(2B):613-8. PubMed ID: 15161002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells: results of an in vitro study.
    Muller M; Chérel M; Dupré PF; Gouard S; Collet M; Classe JM
    Eur Surg Res; 2011; 46(3):139-47. PubMed ID: 21372578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of response to radiation, hyperthermia and cisplatin in parental and polymerase beta knockout cells.
    Raaphorst GP; Ng CE; Yang DP
    Int J Hyperthermia; 2002; 18(1):33-9. PubMed ID: 11820466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elimination of dose-rate effects by mild hyperthermia.
    Wang Z; Armour EP; Corry PM; Martinez A
    Int J Radiat Oncol Biol Phys; 1992; 24(5):965-73. PubMed ID: 1447038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.
    Jones E; Alvarez Secord A; Prosnitz LR; Samulski TV; Oleson JR; Berchuck A; Clarke-Pearson D; Soper J; Dewhirst MW; Vujaskovic Z
    Int J Hyperthermia; 2006 Mar; 22(2):161-72. PubMed ID: 16754599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells.
    Barnes AP; Miller BE; Kucera GL
    Gynecol Oncol; 2007 Feb; 104(2):443-50. PubMed ID: 16996114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuation of chronic thermotolerance by KNK437, a benzylidene lactam compound, enhances thermal radiosensitization in mild temperature hyperthermia combined with low dose-rate irradiation.
    Sakurai H; Kitamoto Y; Saitoh J; Nonaka T; Ishikawa H; Kiyohara H; Shioya M; Fukushima M; Akimoto T; Hasegawa M; Nakano T
    Int J Radiat Biol; 2005 Sep; 81(9):711-8. PubMed ID: 16368649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation enhanced efficiency of combined electromagnetic hyperthermia and chemotherapy of lung carcinoma using cisplatin functionalized magnetic nanoparticles.
    Babincová M; Kontrisova K; Durdík S; Bergemann C; Sourivong P
    Pharmazie; 2014 Feb; 69(2):128-31. PubMed ID: 24640602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of cisplatin and radiation in cell culture: effect of duration of exposure to drug and timing of irradiation.
    Gorodetsky R; Levy-Agababa F; Mou X; Vexler AM
    Int J Cancer; 1998 Feb; 75(4):635-42. PubMed ID: 9466668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiosensitization by Cisplatin treatment in Cisplatin-resistant and sensitive human ovarian-carcinoma cell-lines.
    Raaphorst G; Wang G; Ng C
    Int J Oncol; 1995 Aug; 7(2):325-30. PubMed ID: 21552842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the cytotoxic interaction between cisplatin and hyperthermia in a human ovarian carcinoma cell line.
    Kimura E; Howell SB
    Cancer Chemother Pharmacol; 1993; 32(6):419-24. PubMed ID: 7903066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
    Yu T; Yang Y; Zhang J; He H; Ren X
    Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective enhancement of radiation response in a C3H mammary carcinoma by cisplatin.
    Overgaard J; Khan AR
    Cancer Treat Rep; 1981; 65(5-6):501-3. PubMed ID: 7195305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperthermic modulation of resistance to cis-diamminedichloroplatinum (II) in human larynx carcinoma cells.
    Beketić-Oresković L; Jaksić M; Oresković S; Osmak M
    Int J Hyperthermia; 1997; 13(2):205-14. PubMed ID: 9147146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of radiosensitization by 41 degrees C hyperthermia during low dose rate irradiation and during pulsed simulated low dose rate irradiation in human glioma cells.
    Raaphorst GP; Ng CE; Shahine B
    Int J Radiat Oncol Biol Phys; 1999 Apr; 44(1):185-8. PubMed ID: 10219813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
    Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
    Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
    El-Senduny FF; Badria FA; El-Waseef AM; Chauhan SC; Halaweish F
    Tumour Biol; 2016 Jan; 37(1):685-98. PubMed ID: 26242260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to pulsed dose rate and low dose rate irradiation with and without mild hyperthermia using human breast carcinoma cell lines.
    Niedbala M; McNamee JP; Raaphorst GP
    Int J Hyperthermia; 2006 Feb; 22(1):61-75. PubMed ID: 16423753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.